Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
GlobalData on MSN4d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoidAs Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Zacks.com on MSN4d
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority TagSanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback